-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
IEX's Q1 results significantly exceeded expectations with operating EPS of $2.00 (up 14% Y/Y) vs. consensus of $1.77, representing a solid $0.23 beat, while organic sales growth accelerated to 5% from Q4's 1%. Orders hit a record $988M (up 10%) as demand broadened across the diversified portfolio. The Health & Science Tech segment was the primary growth driver, with 17% reported and 11% organic sales growth, plus 100 bps of adjusted EBITDA margin expansion to 26.6%, underpinned by AI-driven data center power solutions demand and semiconductor applications. Management raised full-year 2026 guidance, projecting organic sales growth of 3%-4% (up from 1%-2%) and adjusted EPS of $8.35-$8.55 (up from $8.15-$8.35). While gross margin declined 40 bps to 44.9% due to unfavorable mix, adjusted EBITDA margin expanded 50 bps to 26%, as 80/20 initiatives bear fruit. In our view, the upgraded outlook reflects an improved demand backdrop across IEX's diversified end markets.